Previous close | 130.63 |
Open | 132.55 |
Bid | 133.60 x 100 |
Ask | 133.76 x 100 |
Day's range | 131.16 - 134.46 |
52-week range | 55.25 - 159.89 |
Volume | |
Avg. volume | 876,814 |
Market cap | 12.634B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 310.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome […]
Q1 2024 Sarepta Therapeutics Inc Earnings Call